Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) ...
Antares Pharma announced that the FDA has approved Otrexup (methotrexate) injection, the first subcutaneous (SC) methotrexate for once-weekly self-administration with a single-dose, disposable ...
OTREXUP (methotrexate) for subcutaneous injection Antares Pharma announced the availability of Otrexup (methotrexate for subcutaneous injection) for once-weekly self-administration with a single-dose ...
“OTREXUP provides an attractive new option that may benefit patients who have had an inadequate response to or are intolerant of oral MTX,” said Paul K. Wotton, PhD, President and Chief Executive ...
Shares of self injection drug delivery technology company Antares Pharma, Inc. (ATRS) are trading higher on Monday after the U.S. Food and Drug Administration approved Otrexup, a once-per-week ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patents RE44846 and RE44847. These patents are reissued ...
EWING, N.J. — A new drug for autoimmune diseases from Antares Pharma that the company calls the first of its kind is now available, the drug maker said Wednesday. Antares announced the availability of ...
Antares Pharma announced its first-quarter results Wednesday morning but failed to impress the market. Shares were down around 3% in midday trading. Here are the highlights from the company's results.
Certain adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal ...
Antares Pharma, Inc. announced that it has received a Notice of Issuance from the U. S. Patent Office for patent number 8,480,631 entitled “Hazardous Agent Injection System.” The claims of this patent ...
Antares ( ATRS) is preparing to launch Otrexup in January 2014; it is the first product it has ever introduced and investor attention is keenly focused on the launch. This report is not a ...
Antares Pharma didn't impress the market with its Q1 results, but a pending Food and Drug Administration decision on Otrexup might be a game changer for this small biotech. Results Antares reported a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results